CDMO Powers 32%, But Baddi Capex and Zambia Slip Narrow the Path
CDMO revenue jumped 38.6% year-on-year, delivering on volume guidance (+20% vs high-teens promised) and holding margins at 14.5%. But near-term capex concentration (Baddi ₹43 Cr operationalizing Q1 FY28) and a three-month slip in Zambia revenue timing (H2 FY27 → Q1 FY28) raise questions on near-term visibility.
₹1,342 Cr
+31.9% YoY, +15.1% QoQ
₹1,115 Cr
+38.6% YoY (83% of total)
14.5%
vs 14.5% prior year (target: 14–15%)
₹115 Cr
+168.3% YoY, +13.5% QoQ
Akums Drugs delivered the quarter on the back of CDMO momentum. Revenue grew 31.9% year-on-year to ₹1,342 Cr, with the contract manufacturing division (₹1,115 Cr, +38.6% YoY) now representing 83% of the business. Volume growth came in at 20% on a net maturity-adjusted (MAT) basis — beating the high-teens guidance issued on the prior call — and margins held steady at 14.5%, within management's 14–15% guidance band. PAT surged 168% to ₹115 Cr, with the conversion from EBITDA (up 106% YoY to ₹195 Cr) to net profit reflecting meaningful operational leverage and reduced API losses rather than one-time items. The tension, however, sits in the near term: capex concentration for a new facility (Baddi, ₹43 Cr invested in H1) operationalizes Q1 FY28, and a three-month revenue timing slip in the Zambia CDMO contract (now Q1 FY28 instead of H2 FY27) narrow visibility through year-end.
What the numbers hold up
CDMO high-teens volume growth Q2-onwards
CDMO volume +20% on Sept net MAT; ₹1,115 Cr revenue (+38.6% YoY)
Supported (beat)
Maintain 14–15% EBITDA margin
Q2 delivered 14.5% (lower end of band); EBITDA ₹195 Cr (+106% YoY)
Supported
Zambia ~₹240 Cr revenue H2 FY27
Supplies scheduled Q4; revenue booking deferred to Q1 FY28 due to election delays
Overstated (3-month slip)
API to reach monthly EBITDA breakeven by end FY27
API EBITDA loss ₹5.7 Cr (vs ₹14 Cr Q2 FY26); 3–4 quarters to breakeven targeted
On track (improving, not yet breakeven)
What changed on this call
Zambia timing slip (downgrade): Prior guidance placed ₹240 Cr of Zambia CDMO revenue in H2 FY27. On this call, management disclosed that mid-year elections delayed government procurement sign-off. Purchase orders are now in hand, and supplies are scheduled for Q4 FY27 dispatch, but the 100–120 day shipping lag pushes revenue recognition to Q1 FY28 — a three-month slip from prior expectation.
CDMO volume beat (upgrade): Guidance from the prior call set CDMO volume growth at high-teens. The quarter delivered 20% volume growth on a net MAT basis, with September showing 50%+ utilization (a healthy absorption level). Pricing remained modest: API prices rose 2–3% quarter-on-quarter, down from 5–7% in the prior-year Q2. The volume beat was driven across existing and new customers, with no single-customer concentration disclosed.
Baddi capex timeline confirmed (new): The Baddi oral solids facility (Himachal Pradesh) is fully funded and on track. Phase 1 (6 billion units of annual capacity, ₹43 Cr capex in H1 FY27) operationalizes Q1 FY28. Management expects it to contribute 10–15% of CDMO business within three years, with phases 2–3 to follow as utilization ramps. Debt/equity funding remains flexible.
API loss narrowing (neutral): The API segment EBITDA loss came in at ₹5.7 Cr, a 60% improvement from the ₹14 Cr loss in Q2 FY26. Management reaffirmed the path to EBITDA breakeven by end FY27 (3–4 quarters from quarter-end), with focus on high-margin products and geographies. No acceleration claimed; the trajectory is orderly.
CDMO volume +20%, beating high-teens guidance; utilization 50%+
Margins held at 14.5% (14–15% band); EBITDA growth 106% YoY
Baddi phase 1 ₹43 Cr capex; operationalizes Q1 FY28 (low-cost asset)
European CDMO dossier filed; supplies to commence FY28 onwards
Zambia revenue pushed H2 FY27 → Q1 FY28 (3-month delay, election-blamed)
Baddi capex concentration; margin support contingent on utilization ramp
API segment EBITDA loss ₹5.7 Cr still material; breakeven 3–4 Q away
Domestic branded +8% YoY; PCPM 2.5 (field force investment drag temporary)
Baddi capex concentration & operational ramp
Medium₹43 Cr H1 capex; margin uplift post-Q1 FY28 operationalization dependent on utilization reaching 60%+. Delay or underutilization would compress group EBITDA by 50–100 bps.
Zambia execution & timing
Medium₹240 Cr revenue now Q1 FY28 vs. H2 FY27 prior guidance. 100–120 day shipping lag post-Q4 dispatch creates FY28 revenue realization risk if production delays.
API segment ongoing loss
Medium₹5.7 Cr EBITDA loss still a drag on group margin. Breakeven by year-end assumes product mix and price improvements; commodities volatility and competition remain.
Domestic branded growth headwind
Low8% growth lags group CAGR. Field force PCPM at 2.5; management expects recovery to 3+ as hires mature. If PCPM stalls, IPM-pace growth (mid-single digit) becomes ceiling.
Oriflame cosmetics acquisition ROI
Low₹56 Cr acquisition; expects 3x revenue uplift over 2 years (unproven). M&A integration and color cosmetics market competitiveness remain.
The market's read
The stock closed at ₹749.8 on 4 Nov 2026, trading between its 20-day SMA (₹736.64) and 50-day SMA (₹764.3), above the 200-day average of ₹607.31. The price sits 36% below its all-time high of ₹1,175.9 but 83% above its 52-week low, suggesting a sharp correction from peak valuations has already priced in execution risk. Volume trends are increasing, a signal of renewed interest.
Ownership tells a shifting story. FII holdings have halved over the past year: from 5.77% (Q4 FY26) to 1.91% (Q1 FY27), with an incremental +0.54pp gain in the most recent quarter (suggesting some stabilization post-correction). DII holdings remain robust at 13.44% (slightly down from 14.35% Q4 FY26), and promoter stake is steady at 75.26%. The FII exit during the run-up from ₹409 (52w low) to ₹838 (52w high) is a sell-on-strength signal. That early-mover FII trimming leaves the stock more promoter-and-DII backed — which is defensive but also implies less institutional tailwind if execution falters.
Read together: the big correction (36% off ATH) has created a margin of safety on fundamentals, but the FII reposition signals that growth assumptions have reset. CDMO momentum is real and beat guidance, but the stock is now priced for Baddi and Zambia execution, not upside surprise. A stumble on either front would test the ₹607 support (200d SMA level, offering structural bid).
1 · Q1 FY28 Baddi operationalization
Phase 1 oral solids (6B units) must achieve design capacity and utilization >50% within first quarter of ops. Margin support (1–2% EBITDA uplift) hinges on this. Any delays → stock test of ₹650 support.
2 · Zambia revenue booking & margin
Q4 FY27 supply dispatch must occur on schedule (no further delays). Q1 FY28 revenue recognition (~₹240 Cr, likely over 2–3 quarters as units ship) and gross margin % are the key metrics.
3 · API breakeven path
Breakeven by end FY27 (per management) means Q4 FY27 should show EBITDA inflection to <₹2 Cr loss or breakeven. Failure to achieve this signals mix/pricing headwinds; continued drag would weigh on group guidance.
Akums Drugs is a steady CDMO operator with structural tailwinds (20%+ volume growth, therapies mix improving), but Q2 is not a breakout moment — it is the maturation of a well-guided business. Management delivered on CDMO volume and margin discipline, but telegraphed near-term headwinds (Baddi capex, Zambia timing slip, API loss still material). The honest read is neither bull nor bear; it is a 12–18 month story where execution on three fronts (Baddi ramp, Zambia revenue, API breakeven) determines whether 2027 is a step-change or a steady-state year.
The number to track from here: EBITDA margin. If Baddi phases in cleanly and Zambia revenue books on schedule, the 14.5% FY27 margin should expand to 15–16% in FY28 and hold. If either stumbles, the 14–15% band becomes ceiling. That single metric summarizes the bet.
Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band
PAT +168.29% YoY · revenue +31.93% · margins expanding
₹1,342.39 Cr
+31.93% YoY
₹114.57 Cr
+168.29% YoY
8.35%
+4.3pp YoY
₹7.37
Akums' consolidated Q2 FY27 (quarter ended 30 September 2026) revenue rose 31.9% YoY to ₹1,342.4 Cr and PAT surged 168.3% YoY to ₹114.6 Cr, with NPM expanding to 8.35% from 4.07% and OPM (EBITDA margin) to 14.51% from 9.28% a year ago — a straightforward YoY growth-cum-margin-expansion quarter, not a one-off: neither this quarter nor the year-ago quarter carried any exceptional item, so the 168% is a clean comparison. Sequentially the picture is milder — revenue +15.1% QoQ and PAT +13.5% QoQ — and OPM actually eased to 14.51% from Q1's 14.97%, so the QoQ print should be read as a continuation of an already-strong base rather than fresh acceleration; NPM similarly ticked down marginally QoQ (8.44%→8.35%).
Q2 FY-2027 vs prior quarters
The margin story sits mainly in CDMO, the largest segment: external revenue grew 38.6% YoY to ₹1,114.9 Cr and segment result (post-depreciation) more than doubled to ₹259.0 Cr from ₹91.6 Cr, comfortably ahead of management's "high-teens volume growth" guidance from the Q1 FY27 call (value growth here is well above that bar, though volume is not separately disclosed). API, flagged for a monthly-EBITDA-breakeven target by end-FY27, narrowed its segment loss to -₹10.1 Cr from -₹18.4 Cr YoY — directionally on track — but the loss actually widened from Q1's -₹8.1 Cr, so the path isn't linear and bears watching. The reported 14.51% OPM sits inside management's reiterated 14–15% EBITDA margin target, meeting guidance, though it is off Q1's print which the company had flagged as running toward the "upper bracket." No public consensus estimate for this specific quarter turned up in a search of brokerage previews; the only available Street benchmark is a ~₹4,920 Cr FY27 full-year revenue consensus (+12.9%), against which Akums is tracking at ₹2,509 Cr for H1 FY27 — broadly consistent, not confirmable on PAT.
The stock went into the print at ₹733.15, down 9.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters.
What the summary numbers don't show
Standalone (parent-only) PAT grew a much slower 39% YoY to ₹32.6 Cr on revenue +27.7% to ₹395.0 Cr — consolidated's outsized growth is driven by subsidiaries, not the parent
Consolidated basic EPS ₹7.37 vs ₹6.53 (Q1 FY27) and ₹2.66 (Q2 FY26)
CDMO high-teens volume growth Q2-onwards. Maintain 14–15% EBITDA margin target; bias toward upper bracket given Q1 strength. Zambia ~₹240 Cr in H2 FY27, similar FY28 at higher-teen EBITDA margins. API to reach monthly EBITDA breakeven by end FY27.
— This quarter: met
On corporate developments, the quarter included Pure and Cure Healthcare's ₹56.0 Cr acquisition of Oriflame India's Roorkee and Noida manufacturing facilities, a stated capacity and color-cosmetics/skincare/wellness expansion move that is incremental to this quarter's P&L (deal completed during the quarter). A subsidiary separately received a ₹52.7 Cr NPPA demand notice in October, outside this result's numbers but a monitorable for the segment's liability position. Management's own press release framing — "PAT surges 168% YoY on margin expansion, revenue up 32%" — matches the reported figures without rounding discrepancies; no prior-quarter outlook from the company is contradicted by this print, and the cautiously-optimistic short-term tone from the August concall is borne out by the margin trajectory, even as Zambia's guided ~₹240 Cr H2 FY27 contribution is not yet separately visible in this segment breakout.
W1
API segment path to monthly EBITDA breakeven by end-FY27 — Q2 segment loss of -₹10.1 Cr widened from Q1's -₹8.1 Cr despite narrowing YoY; watch Q3 trajectory
W2
OPM within the 14–15% guided band (14.51% this quarter, down from Q1's 14.97% 'upper bracket' print) — watch whether it holds or slips further toward the lower end in H2
W3
Zambia ramp toward management's guided ~₹240 Cr H2 FY27 revenue at higher-teen EBITDA margins — not yet separately visible in this quarter's segment disclosure
Clean digital filing, both schedules fully legible; no exceptional items in Q2 FY27, Q1 FY27 or Q2 FY26 quarters (FY26 full-year had a ₹20.0 Cr exceptional item, not in any compared quarter) so no raw-vs-adjusted PAT split needed. Consolidated PAT of ₹114.57 Cr includes ₹1.71 Cr non-controlling interest; owners'-share PAT is ₹112.85 Cr. Standalone PAT grew only ~39% YoY vs consolidated's 168% YoY — the gap is subsidiary-level margin improvement, not the parent. Ongoing IT-department search/seizure tax demand (₹156.0 Cr consolidated, block period FY19-FY25) carries no P&L adjustment per management/legal assessment.
Strong CDMO, margins held; near-term capex & Zambia slip limit upside
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met CDMO growth (20%+ vs high-teens), margin guidance (14.5% in 14–15% band), but Zambia pushed Q4→Q1 due to elections.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered on CDMO momentum (31.9% revenue, 20%+ volume growth) and margin discipline (14.5%), but near-term catalysts (Baddi capex, Zambia delayed from H2 to Q1 FY28) and API overhang limit upside. Long-term CDMO trajectory intact; short-term execution risk elevated.
₹1342 Cr
Revenue · +31.9% YoY₹115 Cr
Reported PAT · +168.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Double-digit volume growth during quarter
METCDMO volume +20% on September net MAT basis; Sept revenue growth 15.6% QoQ
EBITDA more than doubled YoY
MET₹195 Cr vs ₹94-95 Cr Q2 FY26 = 106% growth
Quarter-on-quarter revenue growth stood at impressive 15%
METRevenue ₹1,018 Cr (Q1) to ₹1,342 Cr (Q2) = 15.1% QoQ
Zambia business ~₹240 Cr in H2 FY27
OVERSTATEDSupplies scheduled Q4; revenue booking Q1 FY28 due to election delays
CDMO high-teens volume growth Q2-onwards
METDelivered 20%+ volume growth on net MAT basis
Earnings quality
What changed since the last call
Zambia revenue timing
DowngradePrior call: ~₹240 Cr H2 FY27. Now: Q4 FY27 supplies → revenue Q1 FY28 (election-related delay 3 months).
CDMO volume growth
UpgradeGuidance high-teens; delivered 20%+ on net MAT. Sept 50%+ utilization vs prior steady-state talk.
API trajectory
NeutralLoss ₹5.7 Cr EBITDA (vs ₹14 Cr Q2 FY26). Path to breakeven confirmed by end FY27; no acceleration claimed.
EBITDA margin guidance
Maintained14–15% target reaffirmed. Q2 landed 14.5% (lower end of range); management says upper bracket bias remains as Baddi scales.
Baddi plant scale-up
NewPhase 1 oral solids 6B units/annum, fully operational Q1 FY28. Expected to deliver 10–15% of CDMO business in 3 years.
The Q&A
Analysts pressed hard on Zambia delay (Saksham Tyagi: credible answer on elections → supplies Q4), European path (questioned dossier approval timeline → 1–2 quarters, realistic), API segment (asked for breakeven timeline → 3–4 quarters, tracked), and Baddi capex phasing (Tyagi & Bhuva: got detailed answers on cost & funding flexibility). Management held firm; no dodging.
Zambia & Europe execution — Saksham Tyagi, Desvelado Advisory
AnsweredZambia: midyear elections delayed govt procurement; now received PO, Q4 supplies → Q1 revenue booking. Europe: dossier filed, approval 1–2 quarters expected.
Baddi capex & timeline — Saksham Tyagi, Desvelado Advisory
AnsweredPhase 1 (6B oral solids) ₹43 Cr capex, operational Q1 FY28. Flexible on debt/internal funds; capex 3x turn on gross margin.
API segment outlook — Saksham Tyagi, Desvelado Advisory
PartialLoss ₹5.7 Cr EBITDA vs ₹14 Cr prior year. No line yet. Endeavor is 3–4 quarters to breakeven. Focus on product mix & geographies.
Domestic branded growth & PCPM — Vansh Gupta, Prescient Capital
AnsweredNo specific guidance. Growth is 8% YoY. PCPM 2.5 for business; therapies (esp. gynae 40–45% of rev) mature. New 200 field force hires dragged PCPM down temporarily.
CDMO therapeutic areas driving growth — Vansh Gupta, Prescient Capital
PartialTherapies growth across contract mfg, existing & new customers, all forms. No specific therapy skew. Fair share in Indian market. R&D upward 3% of CDMO revenue.
Oriflame acquisition contribution — Divya Daga, Vijit Global Securities
AnsweredBought for ₹56 Cr (color cosmetics entry). Peak 3x revenue expected over couple of years; minimal PAT contribution this year as ramp phase.
Baddi facility timeline & capex phasing — Divya Daga, Vijit Global Securities
AnsweredPhase 1 (6B units oral solids) operationalizes Q1 FY28. Expected 10–15% of CDMO business 3 years out. Capex phased as maturity achieved.
Oreflame ROI & Baddi payback — Meet Bhuva, Entrigity Ventures & Partnerships
AnsweredFlexible funding: loans available at lower cost; will use own funds if beneficial. Capex historically 3x turn on gross margin.
CDMO pricing power & API prices — Axay Shah, VVD Asset Managers
AnsweredAPI prices up 2–3% QoQ (vs 5–7% last Q2 FY26). Slight upward trajectory only; commodities-dependent. Q4 onwards pricing uncertain.
R&D expense & R&D headcount — Praveen Jayaraman, Avendus Spark Institutional Equities
AnsweredBroadly 3% of revenue (₹130–odd crore). Upward 3–3.5% for regulated markets. Manpower: 375 scientists, 100-odd support staff.
Major contract pipeline — Praveen Jayaraman, Avendus Spark Institutional Equities
DodgedNothing disclosed as of now. Rest over here. Endeavor remains how do we grow the business.
Domestic branded growth drivers & margin path — Sangeeta Purushottam, Cogito Advisors
AnsweredCDMO fast-growing, 56–57 rank in India (almost 90–92% revenue from India). Manpower investment (450 hires on sales force) dragged EBITDA. Path forward: higher PCPM (above 3), new product launches (half of growth).
Trade generics exit strategy — Sangeeta Purushottam, Cogito Advisors
AnsweredTrade generics was historical (₹400-odd Cr at peak); now ₹56–57 Cr rank. Kepts pockets profitable, lean structure. No discontinuation of branded play. Tier 4 geographies, distributor network kept lean; not losing money.
Guidance
No explicit FY27/FY28 revenue target; CDMO high-teens vol growth (Q2 delivered 20%+)
HighCDMO +38.6% YoY on strong underlying volumes; utilization 50%+; IPM penetration expanding.
Maintain 14–15% EBITDA margin; bias toward upper bracket
HighQ2 delivered 14.5% (within band). Baddi ramp & API breakeven expected to support margin lift post-Q1 FY28.
H1 capex ₹210 Cr (Oreflame ₹56 Cr + Baddi ramp); flexible debt/equity funding
MediumBaddi phase 1 ₹43 Cr; phases 2–3 TBD. Company targeting 3x turn on gross margin; no specific guidance for FY27/28 total capex.
Risks the call surfaced
CDMO customer concentration
MediumCDMO ₹1,115 Cr (83% of revenue). Volume growth 20%+ driven by existing & new customers, but no single-customer exposure detail given.
Zambia execution delay
MediumPrior guidance ₹240 Cr H2 FY27; now Q4 FY27 supplies → Q1 FY28 revenue (100–120 day shipping lag + earlier election delays).
API segment ongoing losses
MediumAPI EBITDA loss ₹5.7 Cr Q2 (vs ₹14 Cr prior year). Breakeven dependent on product mix optimization & price recovery (commodities-volatile).
Baddi capex concentration & ramp risk
Medium₹43 Cr capex in H1 FY27 for Baddi phase 1 (6B units oral solids). Operationalization Q1 FY28; margin support contingent on utilization ramp.
Domestic branded growth headwind
LowDomestic branded only 8% YoY; PCPM 2.5 due to 450 new field force hires. IPM-pace growth guidance implies mid-single digit outlook.
Management
Score 7/10. Clear on business segments & drivers; transparent on Zambia delays (election-blamed). Cautious on near-term; no vague promises. Detailed on capex phasing & R&D. Met CDMO guidance (20%+ vol growth vs high-teens prior). Margin on target (14.5% in 14–15% band). Zambia timing slip but PO in hand. API improving (loss ₹14 Cr → ₹5.7 Cr).
1 · Q1 FY28
Baddi phase 1 operationalizes; Zambia supplies booked; API approaches breakeven
2 · H2 FY28
European CDMO supplies commence; Baddi phases 2–3 ramp begin
3 · Q4 FY27
Zambia supplies dispatched (100–120 days shipping lag); margin cushion from higher-margin CDMO
Long-term CDMO trajectory intact; short-term execution risk elevated.